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PET was performed at a median of 70 days after treatment. PET 
responses were; CMR n=40 (45%), PMR n=32 (36%), SMD n= 5 (6%) 
and PMD 11 (13%). Median survival for CMR and non-CMR patients 
was 31 and 11 months respectively (P=0.0001). One year survival for 
CMR and non-CMR patients was 93% and 47% respectively and 2 
years survival was 62% and 30% respectively. Attainment of CMR 
after radical RT/chemoRT for NSCLC bestowed superior freedom from 
both local and distant relapse. Other series have reported a strong corre-
lation between PET response and outcome. Increased FDG uptake can 
be observed due to inﬂammation in normal tissues after RT, but with 
careful interpretation this does not prevent accurate response assess-
ment. Recent pilot studies suggest that PET response measured during a 
course of RT has prognostic signiﬁcance and could potentially be used 
to dynamically modify RT target volumes or reﬁne dose distributions to 
target the more resistant tumor regions. 
PET response after Neoadjuvant Therapy
Several trials have investigated the correlation between early PET 
response to neoadjuvant chemotherapy 4, 5 or chemoRT 6 prior to 
surgery and histopathological response and/or survival. There have 
been conﬂicting reports of the utility of this information, but a strong 
but imperfect correlation between PET ﬁndings and histopathological 
response exists. PET information could potentially be used to select 
patients for surgery and at the very least could exclude those who have 
disease progression from unnecessary aggressive therapy.
PET response after Chemotherapy in advanced NSCLC
Because FDG PET scans can give an indication of response long before 
there are conclusive changes on CT scans, the use of PET to assess 
early response to chemotherapy in advanced NSCLC has seemed an 
attractive idea. Indeed there is evidence that a signiﬁcant early reduc-
tion in the SUV has prognostic signiﬁcance 7. PET is becoming more 
widely used in clinical trials to test investigational agents for activity. 
It may be used in routine clinical practice to allow an early change in 
chemotherapy or cessation of treatment in patients who show no signs 
of a useful response. This may prevent unnecessary toxicity in patients 
who would otherwise receive multiple cycles of chemotherapy before 
CT could show that treatment was ineffective.
Conclusions
As PET scanning becomes more widely available and accessible, it is 
likely to become the investigation of choice for response assessment in 
NSCLC in a wide range of clinical situations. 
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Exciting new therapeutic approaches for locally advanced lung cancers 
has been realized recently through a greater understanding of the cancer 
cell signaling pathway. Therapeutic agents designed to disrupt critical 
components of the growth factor signaling pathway such as the epider-
mal growth factor receptor cascade have demonstrated response rates 
of approximately 10% in patients with chemo-refractory lung cancers. 
The JBR-21 trial provided level 1 evidence that even as monotherapy, 
Tarceva, an EGFR TKI, improved survival in patients with stage IV 
NSCLC patients who progressed following chemotherapy (1). Where 
are we with targeted therapies and radiation in the management of 
non-small cell lung cancer? Preclinical data conﬁrmed that blockade 
of the EGFR pathway would enhance the cytotoxic effects of ionizing 
radiation (2). This was a rationale hypothesis since radiation appears to 
amplify EGFR signaling (3) along with other aspects of the cancer sur-
vival process including angiogenic proteins such as vascular endotheli-
al growth factor (VEGF). Recent randomized trials have conﬁrmed the 
efﬁcacy of combining an EGFR inhibitor, cetuximab, with radiotherapy 
in patients with locally advanced head and neck cancer (4). 
How can we tell who will respond to EGFR inhibition? Clinical data 
has emerged recently to assist in predicting responders versus non-re-
sponders to small molecule EGFR-TKIs. Speciﬁc characteristics that 
appear to be related to response to EGFR-TKIs include mutations to the 
EGFR domain as well as specimens that are both IHC and FISH posi-
tive for gene ampliﬁcation of the EGFR (5-9). Regarding the former, 
data emerged over the past several years that correlated mutations in 
the EGFR TK domain to geﬁtinib-responsiveness in NSCLC. Interest-
ingly, a majority of mutations in EGFR have been observed primar-
ily in the Asian population and similar ﬁndings have been seen in 
erlotinib-sensitive patients. We also are aware that mutations are more 
common in never-smokers, women, Asians, and patients with adeno-
carcinoma, likely explaining the association of these characteristics 
with TKI response. Interestingly, there is a paucity of data correlating 
mutations, or FISH positivity to response to monoclonal antibodies 
against the EGFR. Pre-clinical information has shown that epithelial to 
mesenchymal transition plays a role in correlating response to erlotinib 
in NSCLC and we have seen that in head and neck cancer as well to 
geﬁtinib (10-11). 
Currently, there are several clinical trials combining EGFR inhibitors 
with radiation in lung cancer. The RTOG (0324) has recently completed 
a Phase II trial combining chemo-radiation with cetuximab in locally 
advanced, stage III NSCLC. Ninty-three patients were entered and 87 
patients were analyzed. At ASCO 2007, early results from this study 
indicated that it was reasonably well tolerated (12). With a median 
follow-up of 14 months a response rate of 62% (n=54) was observed 
with a 12 month overall survival (OS) of 68%. Adverse events related 
to treatment include 20% of patients with grade 4 hematologic toxici-
ties and 7 patients with grade 3 esophagitis. Three patients reportedly 
died of pulmonary complications (adult respiratory distress syndrome, 
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pneumonitis, and hypoxia). A phase II trial evaluating the response and 
toxicity to intensity modulated radiation in combination with cetuximab 
in locally advanced non-small cell lung cancer for patients ineligible 
for chemo-radiation is under investigation. This trial, termed NEAR 
(Non-small cell lung cancer, (Erbitux (And (Radiotherapy) delivers 66 
Gy to all sites of gross disease with weekly cetuximab followed by an 
additional 13 weeks of maintanance cetuximab (13). 
Clinical responses to EGFR inhibitors in lung cancer are ~10% so 
there clearly is room for improvement. Perhaps combining agents 
that perturb other critical downstream signaling pathways with EGFR 
inhibitors might improve response further. Examples include combina-
tions of mTOR inhibitors with EGFR inhibitors (14). Blocking other 
pathways may prevent acquired resistance from developing to EGFR 
inhibitors. This includes combinations of anti-angiogenic agents such 
as bevacizumab, an antibody against the vascular endothelial growth 
factor, with erlotinib in patients with recurrent non-squamous NSCLC. 
This combination was shown to be safe with promising activity (15). 
Combinations of celecoxib and EGFR inhibition enhanced the effects 
of radiation in NSCLC (16) and may provide a roadmap for future 
clinical trials with combinations of targeted agents and radiotherapy. 
This discussion will discuss some underlying preclinical concepts con-
cerning EGFR inhibitors and radiation, comment on the recent clinical 
trials combining EGFR inhibitors and radiation in lung cancer and 
ﬁnally, offer opinions regarding issues related to predicting response to 
these new agents. In addition, we will explore how we can incorporate 
other types of “targeted therapies” into the armamentarium in an effort 
to improve outcomes further with radiation therapy. 
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Tumor hypoxia has been shown to affect the malignant progression of 
transformed cells and their response to therapy through the selection of 
tumor cells with diminished apoptotic potential and increase metastatic 
ability 1. Past studies have demonstrated a strong correlation between 
pretreatment tumor pO
2
 and tumor control and survival in patients 
with solid cancers 2-5. Indirect assessment of tumor hypoxia with either 
imaging studies or immunohistochemical staining (IHC) for hypoxia-
induced proteins suggest that tumor hypoxia is prevalent in non-small 
cell lung cancers (NSCLC) and confers an adverse impact on treatment 
outcomes 6-13. To directly assess the role of tumor hypoxia in NSLCL, 
we performed a prospective study to determine the impact of tumor 
hypoxia on outcome in 20 patients with resectable NSCLC using the 
Eppendorf pO
2
 histograph, CA IX staining, plasma osteopontin (OPN) 
levels and gene expression proﬁling. We correlated the expression of 
selected hypoxia-related genes and proteins to tumor pO
2
 and to treat-
ment outcomes. We conﬁrmed that tumor hypoxia existed in NSCLC 
and was associated with elevated expression of Osteopontin (OPN) in 
the plasma and Carbonic Anhydrase IX on tumor tissues. Tumor hy-
poxia and the increased expression of OPN and OPN receptor (CD44) 
also adversely affected prognosis in these patients. 14
Lysyl oxidase (LOX) is an amine oxidase that cross-links collagens 
and elastins in the extracellular matrix. We have shown that LOX 
expression was associated with tumor hypoxia in patients with breast 
and head and neck cancer. High LOX expression levels in the pri-
mary tumor correlated with a reduction in metastasis-free and overall 
survival in these patients. We demonstrated that LOX inhibition by 
different means, including genetic (LOX shRNA), chemical (beta-
aminoproprionitrile or BAPN, a chemical inhibitor of LOX enzymatic 
function) or antibody (anti-LOX blocking antibody), eliminated the 
formation of metastases in an orthotopic breast cancer model and this 
occurs through prevention of cell invasion and deterrence of meta-
static growth.15 We have also extended these observations to NSCLC. 
Patients with high tumoral LOX mRNA expression had signiﬁcantly 
lower survival compared with those with low LOX-expressing tumors. 
Decrease LOX expression with shRNA in A549 human NSCLC cells 
resulted in improved survival in an orthotopic lung tumor model us-
ing intravenous tumor implantation. Survival of mice bearing control 
tumors was increased by treatment with either LOX-targeting antibody 
or a LOX inhibitor (BAPN) that were administered 2-3 weeks after 
tumor implantation. Histologically, this was associated with a decrease 
in the overall tumor burden with less lung, bone and liver metastases in 
treated mice. 
